The solution structure of the N-terminal domain of human vitronectin - Proximal sites that regulate fibrinolysis and cell migration

被引:35
作者
Mayasundari, A
Whittemore, NA
Serpersu, EH
Peterson, CB
机构
[1] Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA
[2] Univ Tennessee, Ctr Excellence Struct Biol, Knoxville, TN 37996 USA
关键词
D O I
10.1074/jbc.M401279200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The three-dimensional structure of an N-terminal fragment comprising the first 51 amino acids from human plasma vitronectin, the somatomedin B (SMB) domain, has been determined by two-dimensional NMR approaches. An average structure was calculated, representing the overall fold from a set of 20 minimized structures. The core residues (18-41) overlay with a root mean square deviation of 2.29 +/- 0.62 Angstrom. The N- and C-terminal segments exhibit higher root mean square deviations, reflecting more flexibility in solution and/or fewer long-range NOEs for these regions. Residues 26-30 form a unique single-turn alpha-helix, the locus where plasminogen activator inhibitor type-1 (PAI-1) is bound. This structure of this helix is highly homologous with that of a recombinant SMB domain solved in a co-crystal with PAI-1 (Zhou, A., Huntington, J. A., Pannu, N. S., Carrell, R. W., and Read, R. J. (2003) Nat. Struct. Biol. 10, 541-544), although the remainder of the structure differs. Significantly, the pattern of disulfide cross-links observed in this material isolated from human plasma is altogether different from the disulfides proposed for recombinant forms. The NMR structure reveals the relative orientation of binding sites for cell surface receptors, including an integrin-binding site at residues 45 47, which was disordered and did not diffract in the co-crystal, and a site for the urokinase receptor, which overlaps with the PAI-1-binding site.
引用
收藏
页码:29359 / 29366
页数:8
相关论文
共 65 条
[11]   Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin [J].
Deng, G ;
Curriden, SA ;
Hu, G ;
Czekay, RP ;
Loskutoff, DJ .
JOURNAL OF CELLULAR PHYSIOLOGY, 2001, 189 (01) :23-33
[12]   Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? [J].
Deng, G ;
Curriden, SA ;
Wang, SJ ;
Rosenberg, S ;
Loskutoff, DJ .
JOURNAL OF CELL BIOLOGY, 1996, 134 (06) :1563-1571
[13]   The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent [J].
Devy, L ;
Blacher, S ;
Grignet-Debrus, C ;
Bajou, K ;
Masson, R ;
Gerard, RD ;
Gils, A ;
Carmeliet, G ;
Carmeliet, P ;
Declerck, PJ ;
Noël, A ;
Foidart, JM .
FASEB JOURNAL, 2002, 16 (02) :147-154
[14]  
Eitzman DT, 1996, BLOOD, V87, P4718
[15]   GLIOBLASTOMA EXPRESSION OF VITRONECTIN AND THE ALPHA-V-BETA-3 INTEGRIN - ADHESION MECHANISM FOR TRANSFORMED GLIAL-CELLS [J].
GLADSON, CL ;
CHERESH, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (06) :1924-1932
[16]  
Gutierrez LS, 2000, CANCER RES, V60, P5839
[17]   H-1 2D-NMR AND DISTANCE GEOMETRY STUDY OF THE FOLDING OF ECBALLIUM-ELATERIUM TRYPSIN-INHIBITOR, A MEMBER OF THE SQUASH INHIBITORS FAMILY [J].
HEITZ, A ;
CHICHE, L ;
LENGUYEN, D ;
CASTRO, B .
BIOCHEMISTRY, 1989, 28 (06) :2392-2398
[18]   IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding [J].
Hymowitz, SG ;
Filvaroff, EH ;
Yin, JP ;
Lee, J ;
Cai, LP ;
Risser, P ;
Maruoka, M ;
Mao, WG ;
Foster, J ;
Kelley, RF ;
Pan, GH ;
Gurney, AL ;
de Vos, AM ;
Starovasnik, MA .
EMBO JOURNAL, 2001, 20 (19) :5332-5341
[19]   Vitronectin deficiency is associated with increased wound fibrinolysis and decreased microvascular angiogenesis in mice [J].
Jang, YC ;
Tsou, R ;
Gibran, NS ;
Isik, FF .
SURGERY, 2000, 127 (06) :696-704
[20]   INVESTIGATION OF EXCHANGE PROCESSES BY 2-DIMENSIONAL NMR-SPECTROSCOPY [J].
JEENER, J ;
MEIER, BH ;
BACHMANN, P ;
ERNST, RR .
JOURNAL OF CHEMICAL PHYSICS, 1979, 71 (11) :4546-4553